SCHEMBL9329658

SCHEMBL9329658

OCCCOCCOCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.54
NAAA Q02083 2/20 0.50
EPHX2 P34913 2/20 0.47
LTA4H P09960 1/20 0.47
TDP1 Q9NUW8 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KDM4E B2RXH2 1/20 0.46
POLB P06746 1/20 0.46
HRH4 Q9H3N8 1/20 0.45
HRH3 Q9Y5N1 1/20 0.45
GBA1 P04062 2/20 0.43
UGCG Q16739 2/20 0.43
GBA2 Q9HCG7 2/20 0.43
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
ADRB3 P13945 1/20 0.43
TEAD3 Q99594 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.42
CA1 P00915 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23249922 1.00 TSHR (0.54) TSHRNAAAEPHX2LTA4HTDP1
SCHEMBL30736988 0.98 TSHR (0.52) TSHRNAAAEPHX2LTA4HTDP1
SCHEMBL23405402 0.96 TSHR (0.50) TSHRNAAAEPHX2LTA4HTDP1
SCHEMBL21068659 0.96 TSHR (0.54) TSHRNAAAEPHX2LTA4HTDP1
SCHEMBL10821588 0.96 TSHR (0.54) TSHRNAAAEPHX2LTA4HTDP1
SCHEMBL25312129 0.96 TSHR (0.54) TSHRNAAAEPHX2LTA4HTDP1
SCHEMBL345616 0.96 TSHR (0.58) TSHRNAAAEPHX2LTA4HTDP1
SCHEMBL21456175 0.94 TSHR (0.52) TSHRNAAAEPHX2LTA4HTDP1
SCHEMBL17941033 0.94 L3MBTL1 (0.53) TSHRNAAAEPHX2LTA4HTDP1
SCHEMBL21068755 0.94 TSHR (0.52) TSHRNAAAEPHX2LTA4HTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026098529-A1 KINESIN KIF18A INHIBITORS AND USE THEREOF SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2026-05-15 WO disclosed
US-20260068886-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL OERTH BIO LLC (US) 2026-03-12 US disclosed
US-12570625-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof NOVARTIS AG (CH) 2026-03-10 US disclosed
US-20250228944-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2025-07-17 US disclosed
EP-4580405-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL Oerth Bio LLC (US) 2025-07-09 EP disclosed
US-12312316-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2025-05-27 US disclosed
WO-2024050016-A9 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL OERTH BIO LLC (US) 2025-04-03 WO disclosed
WO-2025049555-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL OERTH BIO LLC (US) 2025-03-06 WO disclosed
EP-4509184-A2 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas Operations, Inc. (US) 2025-02-19 EP disclosed
CN-112261970-B 3- (5-Hydroxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and their use in the treatment of IKAROS family zinc finger 2 (IKZF 2) dependent diseases 诺华股份有限公司 2025-02-07 CN disclosed
WO-2017030814-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS Arvinas, Inc. (US) 2017-02-23 WO disclosed
WO-2017030814-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS Arvinas, Inc. (US) 2017-02-23 WO disclosed
WO-2016118666-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR Arvinas, Inc. (US) 2016-07-28 WO disclosed
WO-2016118666-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR Arvinas, Inc. (US) 2016-07-28 WO disclosed
US-20160214972-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2016-07-28 US disclosed
US-20160214972-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2016-07-28 US disclosed
US-20160214972-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2016-07-28 US disclosed
EP-0381974-B1 Thiophene azo dyes with a coupling component based on m-phenylene diamine BASF AG (DE) 1994-03-16 EP disclosed
US-5145952-A Blue, textiles BASF AKTIENGESELLSCHAFT (DE) 1992-09-08 US disclosed
EP-0381974-A2 Thiophene azo dyes with a coupling component based on m-phenylene diamine BASF Aktiengesellschaft (DE) 1990-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160214972-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ESRRA, MDM2 TSHR 1988/4885NAAA 3246/4885EPHX2 1342/4885
US-12570625-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof IKZF1, IKZF2, BCL6 TSHR 3099/4885NAAA 4869/4885EPHX2 3188/4885
US-12312316-B2 Compounds and methods for the targeted degradation of androgen receptor AR, MDM2, ESRRA TSHR 1939/4885NAAA 3630/4885EPHX2 1647/4885
US-20250228944-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT TSHR 3658/4885NAAA 3111/4885EPHX2 1526/4885
US-20260068886-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL CRBN, STUB1, CUL1 TSHR 2053/4885NAAA 4441/4885EPHX2 2474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.